Springworks Therapeutics Inc Revenue Growth Rates (SWTX), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Springworks Therapeutics Inc   (NASDAQ: SWTX)
 

SWTX's Revenue Growth by Quarter and Year

Springworks Therapeutics Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

SWTX Revenue (in millions $) FY 2025 FY 2024 FY 2023 FY 2022
4th Quarter December -
3rd Quarter September -
2nd Quarter June -
1st Quarter March 49.09
FY 49.09

SWTXs Annual Revenue
Springworks Therapeutics Inc 's Revenue in the fiscal year 2024 $ 191.59 millions
Springworks Therapeutics Inc 's Revenue in the fiscal year 2023 $ 5.45 millions
Springworks Therapeutics Inc 's Revenue in the fiscal year 2022 $ 0.00 millions
Springworks Therapeutics Inc 's Revenue in the fiscal year 2021 $ 0.00 millions
Springworks Therapeutics Inc 's Revenue in the fiscal year 2020 $ 35.00 millions




SWTX Revenue first quarter 2025 Y/Y Growth Comment
Springworks Therapeutics Inc achieved in the first quarter 2025, above Company average Revenue surge of 133.64% year on year, to $ 49.09 millions.

Looking into first quarter 2025 results within Biotechnology & Pharmaceuticals industry 16 other companies have achieved higher Revenue growth. While Springworks Therapeutics Inc ' s Revenue doubling of 133.64% ranks overall at the positon no. 367 in the first quarter 2025.


SWTX Revenue ( Y/Y Growth %) 2025
 2024 2023 2022
4th Quarter December - 1029.36 % - -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March 133.64 % - - -
FY   - 3415.41 % - -

Financial Statements
Springworks Therapeutics Inc 's first quarter 2025 Revenue $ 49.09 millions SWTX's Income Statement
Springworks Therapeutics Inc 's first quarter 2024 Revenue $ 21.01 millions Quarterly SWTX's Income Statement


SWTX Revenue (Quarter on Quarter Growth %)

 2025
 2024 2023 2022
4th Quarter December - 24.85 % - -
3rd Quarter September - -17.46 % - -
2nd Quarter June - 184.29 % - -
1st Quarter March -20.25 % 285.5 % - -
FY (Year on Year)   - 3415.41 % - -


Back to SWTX Growth rate Comparisons >> Back to SWTX Growth rate Comparisons >>


Revenue first quarter 2025 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #17
Healthcare Sector #94
Overall #367

Revenue Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Revenue first quarter 2025 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #17
Healthcare Sector #94
Overall #367
Revenue Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Revenue by Quarter for the Fiscal Years 2022, 2023, 2024, 2025

Springworks Therapeutics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
285.64 % 91.43 % -20.25 %
(Mar 31 2024)  


SWTX's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2025 Springworks Therapeutics Inc disclosed fall in Revenue from the fourth quarter by -20.25% to $ 49.09 millions, from $ 61.55 millions achived in the previous reporting period.

Although periodic circumstance commonly energize I. Quarter 2025 Revenue, this plainly could not be substantial to rescue Biotechnology & Pharmaceuticals's company achievement, Most analysts pointed out.

Within Biotechnology & Pharmaceuticals industry 53 other companies have achieved higher Revenue quarter on quarter growth. While Springworks Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 3432.


Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #54
Healthcare Sector #476
Overall #3432
Revenue Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #54
Healthcare Sector #476
Overall #3432
Revenue Q/Q Growth Statistics
High Average Low
285.64 % 91.43 % -20.25 %
(Mar 31 2024)  


SWTX's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2025 Springworks Therapeutics Inc disclosed fall in Revenue from the fourth quarter by -20.25% to $ 49.09 millions, from $ 61.55 millions achived in the previous reporting period.

Although periodic circumstance commonly energize I. Quarter 2025 Revenue, this plainly could not be substantial to rescue Biotechnology & Pharmaceuticals's company achievement, Most analysts pointed out.

Within Biotechnology & Pharmaceuticals industry 53 other companies have achieved higher Revenue quarter on quarter growth. While Springworks Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 3432.


Springworks Therapeutics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Mar 31 2025)		 12 Months Ending
(Dec 31 2024)		 12 Months Ending
(Sep 30 2024)		 12 Months Ending
(Jun 30 2024)		 12 Months Ending
(Mar 31 2024)
Cumulative Revenue 12 Months Ending $ 219.67 $ 191.59 $ 135.49 $ 0.00 $ 0.00
Y / Y Revenue Growth (TTM) - - - - -
Year on Year Revenue Growth Overall Ranking # # # # #
Seqeuential Revenue Change (TTM) 14.66 % 41.41 % - - -
Seq. Revenue Growth (TTM) Overall Ranking # 367 # 0 # 0 # 0 # 0


Cumulative Revenue growth Comment
Springworks Therapeutics Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 133.64% year on year, to $ 220 millions if the fiscal year would have ended in Mar 31 2025.
Springworks Therapeutics Inc 's trailing twelve months Revenue growth was higher than company's average 0% and higher than % growth in Dec 31 2024. And, Springworks Therapeutics Inc realized the fastest Revenue growth, in Biotechnology & Pharmaceuticals industry.
But from twelve months ended Dec 31 2024 rise was beneth at 14.66 % from $191.59 millions achieved in the period from Dec 31 2024 to Mar 31 2024.
Still this was evidence of convincing trend, while the usual Q/Q TTM gain stands at 0%.

Springworks Therapeutics Inc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
 0 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 17
Sector # 94
S&P 500 # 367
Cumulative Revenue growth Comment
Springworks Therapeutics Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 133.64% year on year, to $ 220 millions if the fiscal year would have ended in Mar 31 2025.
Springworks Therapeutics Inc 's trailing twelve months Revenue growth was higher than company's average 0% and higher than % growth in Dec 31 2024. And, Springworks Therapeutics Inc realized the fastest Revenue growth, in Biotechnology & Pharmaceuticals industry.
But from twelve months ended Dec 31 2024 rise was beneth at 14.66 % from $191.59 millions achieved in the period from Dec 31 2024 to Mar 31 2024.
Still this was evidence of convincing trend, while the usual Q/Q TTM gain stands at 0%.
The momentum is even more impressive from twelve months ended Dec 31 2024 exhibited at 14.66 % increase from $191.59 millions in the period from Dec 31 2024 to Mar 31 2024.

Springworks Therapeutics Inc achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 17
Sector # 94
S&P 500 # 367




Other Revenue Growth
Biotechnology & Pharmaceuticals Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
SWTX's Revenue Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue fall for the quarter ending Mar 31 2025 within Healthcare SectorY/Y Change %Revenue for the quarter ending Mar 31 2025
Hyperion Defi inc 194.81%$ 194.813 millions
Myomo Inc 191.29%$ 191.285 millions
Immunome Inc 184.35%$ 184.354 millions
Tarsus Pharmaceuticals Inc 183.68%$ 183.679 millions
Meiragtx Holdings Plc176.33%$ 176.327 millions
Ss Innovations International Inc174.91%$ 174.908 millions
Dar Bioscience Inc 173.35%$ 173.350 millions
Ethema Health Corporation 170.58%$ 170.577 millions
Zymeworks Inc 170.29%$ 170.289 millions
Protalix Biotherapeutics inc 169.82%$ 169.824 millions
Opus Genetics Inc 155.41%$ 155.406 millions
Prime Medicine Inc 146.02%$ 146.024 millions
Beyond Air Inc 145.11%$ 145.106 millions
Eton Pharmaceuticals Inc 140.63%$ 140.631 millions
C4 Therapeutics Inc 138.17%$ 138.170 millions
Springworks Therapeutics Inc 133.68%$ 133.681 millions
Lyell Immunopharma Inc 133.33%$ 133.333 millions
Generation Bio Co 114.91%$ 114.905 millions
Kymera Therapeutics Inc 114.83%$ 114.834 millions
Newamsterdam Pharma Company N v 112.56%$ 112.562 millions
Hims and Hers Health Inc 110.61%$ 110.608 millions
Eyepoint Inc 109.29%$ 109.286 millions
Bluebird Bio Inc 108.43%$ 108.432 millions
Legend Biotech Corporation107.52%$ 107.523 millions
Nuo Therapeutics Inc 106.49%$ 106.491 millions
Vyne Therapeutics Inc 106.12%$ 106.122 millions
Qt Imaging Holdings Inc exact Name Of Registrant As Specified In Its Charter _______________________105.44%$ 105.439 millions
Xencor Inc104.61%$ 104.613 millions
Coya Therapeutics Inc 103.32%$ 103.318 millions
Alaunos Therapeutics Inc 100.00%$ 100.000 millions


About Springworks Therapeutics Inc Revenue Growth Rates (SWTX), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Springworks Therapeutics Inc (CIK 1773427).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001773427-25-000015
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Springworks Therapeutics Inc ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.